Loading clinical trials...

Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis | Clinical Trials | Clareo Health

RECRUITINGNA

Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis

Randomized, Double-blind Clinical Trial on the Efficacy and Safety of Gut Microbiota Transplantation (FMT) in the Treatment of Moderate to Severe Acute Pancreatitis

NCT07153809•Changhai Hospital

View on ClinicalTrials.gov

Summary

This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.

Detailed Description

This study is a single center, randomized controlled trial. After the start of the study, 80 patients with acute moderate to severe acute pancreatitis were randomly selected according to inclusion and exclusion criteria and divided into an intervention group (n=40) and a control group (n=40) to explore the safety and efficacy of FMT in preventing late complications of acute moderate to severe acute pancreatitis.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age: 18-70 years old Diagnosis: Meets the diagnostic criteria for severe acute pancreatitis (SAP)
•Organ function: There may be organ failure and systemic complications that can be recovered within 48 hours
•Stage of the disease: Approximately 2 weeks after onset (non acute phase), accompanied by accumulation of pancreatic fluid volume, and significant improvement in CTSI score compared to before (grade II)
•Nutritional support: Enteral nutrition tube has been left in place Feasibility of transplantation: No absolute contraindications for gut microbiota transplantation
•Informed Consent: Voluntarily sign a written informed consent form
•Gastrointestinal status:
•Abdominal pressure (bladder pressure measurement)\<12mmHg ◦ Existence of spontaneous defecation/exhaust Significant improvement in abdominal distension compared to before

Exclusion Criteria

•Serious complications: combined gastrointestinal bleeding or intestinal fistula
•Special population: Pregnant or lactating women
•Informed refusal: Failure to sign informed consent form
•Basic organ dysfunction: Prior to admission, there were chronic organ dysfunction in the heart, lungs, liver, kidneys, or blood system Malignant tumor: Suffering from incurable malignant tumors
•Immune abnormalities:
•Autoimmune diseases
•◦ Immunosuppression status (solid organ/bone marrow transplantation history, AIDS, long-term use of immunosuppressants/hormones)
•Enteral nutrition intolerance: unable to meet 50% of calorie requirements due to severe diarrhea, fibrotic intestinal stenosis, severe gastrointestinal edema, high flow intestinal fistula, etc
•Systemic infection: meets the diagnostic criteria for systemic inflammatory response syndrome (SIRS)
•Antibiotic dependence: broad-spectrum antibiotic intervention is required for combined extraintestinal organ infections
+2 more criteria

Locations (2)

Changhai Hospital

Shanghai, Shanghai Municipality, China

Changhai Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

October 12, 2024

Primary Completion Date

December 31, 2026

Completion Date

December 31, 2026

Last Updated

September 4, 2025

Enrollment

ESTIMATED participants

Conditions

Acute PancreatitisSevere Acute Pancreatitis

Interventions

FMT

PROCEDURE

Placebo

PROCEDURE

Contacts

Kong Xiang yu, associate professor

CONTACT

13564644397 xiangyukong185@hotmail.com

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

NCT07171112

Pancreatitis, ChronicPancreatitis, Acute+2 more

View study

RECRUITING

DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis

NCT06899087

Acute Pancreatitis

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis

Inclusion Criteria

Exclusion Criteria

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis

Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis

Preventing Recurrent 'Idiopathic' Acute Pancreatitis Through Laparoscopic Cholecystectomy (PICUS-2)

PrEveNtion of Biliary Events After Acute Pancreatitis in NonSUrgicaL PAtients: PENINSULA Trial

Rectal Indomethacin vs Intravenous Ketorolac